Brokerages Set HTG Molecular Diagnostics Inc (NASDAQ:HTGM) PT at $5.75

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has received an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $5.25.

Several brokerages have recently commented on HTGM. HC Wainwright dropped their target price on shares of HTG Molecular Diagnostics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Zacks Investment Research cut shares of HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, August 10th. Canaccord Genuity restated a “buy” rating and issued a $3.00 target price on shares of HTG Molecular Diagnostics in a research report on Tuesday, August 13th. Finally, ValuEngine upgraded shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

HTG Molecular Diagnostics stock traded up $0.05 during midday trading on Friday, hitting $1.00. The company’s stock had a trading volume of 245,800 shares, compared to its average volume of 234,865. HTG Molecular Diagnostics has a 1-year low of $0.93 and a 1-year high of $5.46. The company has a debt-to-equity ratio of 0.87, a current ratio of 3.49 and a quick ratio of 3.34. The company has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $2.13. The company has a market cap of $27.39 million, a price-to-earnings ratio of -1.67 and a beta of 1.55.

HTG Molecular Diagnostics (NASDAQ:HTGM) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). HTG Molecular Diagnostics had a negative return on equity of 95.77% and a negative net margin of 79.96%. The business had revenue of $5.80 million during the quarter, compared to analyst estimates of $5.54 million. Sell-side analysts forecast that HTG Molecular Diagnostics will post -0.59 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in HTGM. Jane Street Group LLC acquired a new position in HTG Molecular Diagnostics during the 4th quarter worth approximately $27,000. Alambic Investment Management L.P. acquired a new position in HTG Molecular Diagnostics during the 2nd quarter worth approximately $38,000. Cowen Prime Services LLC acquired a new position in HTG Molecular Diagnostics during the 1st quarter worth approximately $50,000. Citadel Advisors LLC increased its position in HTG Molecular Diagnostics by 153.9% during the 2nd quarter. Citadel Advisors LLC now owns 38,525 shares of the medical research company’s stock worth $64,000 after purchasing an additional 23,351 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in HTG Molecular Diagnostics during the 4th quarter worth approximately $151,000. Institutional investors and hedge funds own 44.62% of the company’s stock.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.

Read More: Hold Rating

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.